We are live on ! Find out more
ELV icon

Elevance Health
ELV

Fund managers haven’t disclosed any holdings of ELV yet.

ELV Hedge Fund Activity: Q1 2026 in Review

1,462 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Elevance Health (ELV) for Q1 2026, worth a combined $57B — down 20% from $71B a quarter earlier.

Sellers outnumbered buyers: 206 funds closed out of ELV and 141 opened new positions — a net loss of 65 holders — while 645 trimmed existing stakes and 482 added.

The largest buyer was Amundi, adding an estimated $525M. The largest seller was T. Rowe Price Associates, cutting an estimated $887M.

  • 1,462 institutional investors held Elevance Health (ELV) as of Q1 2026, down from 1,553 in Q4 2025.
  • Funds reported $57B of Elevance Health stock for Q1 2026, down 20% quarter-over-quarter.
  • 141 funds opened new Elevance Health positions in Q1 2026 and 206 closed out, a net change of -65 holders.
  • The largest Elevance Health buyer in Q1 2026 was Amundi, an estimated $525M added.
  • The largest Elevance Health seller in Q1 2026 was T. Rowe Price Associates, an estimated $887M sold.

Based on aggregated 13F filings for Q1 2026.